The Latest Breaking News from Roche

Celldex took aim at Roche and Novartis' blockbuster hives drug on Friday with a small study that showed promise — but CLDX stock tumbled.

The Russell 1000 Value index has slumped 12% so far this year, while Russell 1000 Growth has dropped 25%.

Competitive advantages and good management are keys to stocks that will cope during tumultuous markets.

Energy, consumer discretionary and tech stocks lead declines in stock market.

Although the heightened market volatility has caused several pharma stocks to slump in price, the sector’s long-term prospects look bright. This sector has been attracting massive investments and could remain in the limelight in the near term. So, we think it should be wise to buy and hold mega-cap pharmaceutical…

A highly watched Alzheimer's drug from Roche failed in its final-stage test, but shares of Roche stock rose as others tumbled.

Here's a roundup of top developments in the biotech space over the last 24 hours:

Roche Holdings AG (OTC:RHHBY) said its Alzheimer's medicine crenezumab did not slow or prevent cognitive decline in people with a specific genetic mutation that causes early-onset disease. Crenezumab did not show a statistically significant clinical benefit in its co-primary endpoints assessing the rate of change in cognitive abilities or episodic memory function. The…

Jab saved one million lives, says Sir Pascal Soriot

Diagnostic companies are racing to develop tests for monkeypox, hoping to tap into a new market as governments ramp up efforts to trace the world's first major outbreak of the viral infection outside of Africa.

An emerging therapeutic area continues to draw interest from large drugmakers.